Belite Bio (BLTE) Projected to Post Quarterly Earnings on Tuesday

Belite Bio (NASDAQ:BLTE) is anticipated to issue its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, November 10, 2025 at 4:30 PM ET.

Belite Bio (NASDAQ:BLTE) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.03). During the same quarter in the previous year, the business posted ($0.31) EPS. On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Price Performance

Shares of BLTE traded down $0.51 during trading hours on Tuesday, hitting $111.89. 55,863 shares of the stock were exchanged, compared to its average volume of 48,664. Belite Bio has a fifty-two week low of $49.00 and a fifty-two week high of $116.24. The business has a 50-day moving average of $77.12 and a 200-day moving average of $67.69. The firm has a market capitalization of $3.56 billion, a P/E ratio of -72.53 and a beta of -1.42.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BLTE. EverSource Wealth Advisors LLC bought a new position in shares of Belite Bio in the second quarter valued at $147,000. Marshall Wace LLP bought a new position in shares of Belite Bio in the second quarter valued at $547,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Belite Bio in the second quarter valued at $190,000. 0.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BLTE has been the subject of several recent analyst reports. Benchmark increased their price objective on shares of Belite Bio from $80.00 to $132.00 and gave the stock a “buy” rating in a research report on Friday. HC Wainwright decreased their price objective on shares of Belite Bio from $100.00 to $98.00 and set a “buy” rating for the company in a research report on Monday, September 15th. Zacks Research upgraded shares of Belite Bio from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 16th. Wall Street Zen upgraded shares of Belite Bio from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Belite Bio in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $113.33.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.